Company intelligence / Profile preview

14U Pharma

Ownership: Private
Development stage: Other

Overview

14U Pharma is an early-stage biotechnology company focused on developing novel small molecule therapeutics for the treatment of autoimmune and inflammatory diseases. The company's primary research efforts are directed toward modulating the IL-17 and IL-23 pathways, which are critical drivers in conditions such as psoriasis and inflammatory bowel disease. By leveraging its expertise in medicinal chemistry, 14U Pharma aims to create oral alternatives to existing injectable biologic therapies. The company is currently advancing its lead candidates through pre-clinical validation to support future clinical development.

Therapeutic areas: DermatologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 14U Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 14U Pharma.

Explore the full profile